Denmark And Ingelheim
COPENHAGEN, Denmark and INGELHEIM, Germany, June 16, 2011 -
- Boehringer
Ingelheim Obtains Global Rights to
glucagon/GLP-1 Dual Agonists, including
ZP2929, Zealand Pharma's
Lead Drug Candidate in This
Class
- Zealand Pharma is
Eligibleto Receive Total
Projected Milestone Payments
of up to €376 million for ZP2929
Today, Zealand Pharma (NASDAQ OMX: ZEAL), a Copenhagen based
biopharmaceutical company, and Boehringer Ingelheim, one of the
world's leading pharmaceutical companies, jointly announced an
exclusive global licence and collaboration agreement for
dual-acting glucagon and GLP-1 receptor agonists for the treatment
of patients with Type-2 diabetes and patients with obesity.
